Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Center LaboratoriesROCO:4123 +1.35%69 Net Margin % is 1,697.72% as of Dec. 2025, which is 23156% above its 10-year median of 7.30. GuruFocus rates ROCO:4123 with a GF Score™ of 69/100 and a GF Value™ of NT$43.04 (Modestly Undervalued). The stock has 6 warning signs investors should review. Among 960 Drug Manufacturers companies, Center Laboratories ranks better than 99.69% on this metric.
The historical rank and industry rank for Center Laboratories's Net Margin % or its related term are showing as below:
ROCO:4123'
s Net Margin % Range Over the Past 10 Years
Min: -71.41 Med: 7.3 Max: 614.89
Current: 614.89
ROCO:4123's Net Margin % is ranked better than 99.69% of 960
companies
in the Drug Manufacturers industry
Industry Median: 5.635
vs ROCO:4123: 614.89
Center Laboratories (ROCO:4123) Net Margin % Explanation
Although Net Income and Earnings-per-Share (EPS) are the most widely used parameter in measuring a company's profitability and valuation, it is the least reliable. The reason is that reported earnings can be manipulated easily by adjusting any numbers such as Depreciation, Depletion and Amotorization and non-recurring items.
But the long term trend of the net margin is a good indicator of the competitiveness and health of the business.
Center Laboratories Net Margin % Related Terms
Center Laboratories Net Margin % Historical Data
* Premium members only.
The historical data trend for Center Laboratories's Net Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - Specialty & Generic subindustry, Center Laboratories's Net Margin %, along with its competitors' market caps and Net Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Center Laboratories Net Margin % vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Center Laboratories's Net Margin % distribution charts can be found below:
* The bar in red indicates where Center Laboratories's Net Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Center Laboratories (ROCO:4123) has a Net Margin % of 1,697.72% as of Dec. 2025. Net margin is the ratio of total net income to net sales. View historical data on Center Laboratories and its competitors. This is 23156% above median its historical median of 7.30. According to the industry distribution chart, Center Laboratories ranks #3 out of 960 companies in the Drug Manufacturers industry, placing it in the top 0.3%.
Is Center Laboratories' Net Margin % too high?
Center Laboratories' current Net Margin % of 1,697.72% is 23156% above median its 10-year median of 7.30. The Drug Manufacturers industry median Net Margin % is 5.64. Center Laboratories' value of 1,697.72% is 30028.1% above this industry median. Based on the distribution chart, Center Laboratories ranks #3 out of 960 companies in the Drug Manufacturers industry, which is in the top quartile — a strong position relative to peers. Overall, Center Laboratories has a GF Score™ of 69/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Center Laboratories' Net Margin % compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, Center Laboratories ranks #3 out of 960 companies for Net Margin %. This places Center Laboratories in the top 0% of its industry — outperforming the majority of peers. The industry median Net Margin % is 5.64. Center Laboratories' value of 1,697.72% is 30028.1% above this benchmark. While the company's 10-year median is 7.30 vs. the industry median of 5.64, Center Laboratories has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Net Margin % for a Drug Manufacturers company?
The median Net Margin % among Drug Manufacturers companies is 5.64, based on 960 companies in the industry. Companies in the top quartile (top 25%) have a Net Margin % significantly above this median, while those in the bottom quartile fall well below. However, Net Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Center Laboratories's current Net Margin % of 1,697.72% is 30028.1% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Net Margin % mean?
A high Net Margin % can signal that a stock is expensive relative to its fundamentals. Net margin is the ratio of total net income to net sales. View historical data on Center Laboratories and its competitors. For the Drug Manufacturers industry, the median Net Margin % is 5.64 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Center Laboratories's current Net Margin % is 1,697.72%, which is 23156% above median its own 10-year median of 7.30. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Center Laboratories stock overvalued right now?
Based on GuruFocus' analysis, Center Laboratories (ROCO:4123) is currently considered Modestly Undervalued. The stock's GF Value™ is NT$43.04, compared to a current price of NT$37.50 — trading 12.9% below its estimated fair value. The current Net Margin % is 1,697.72%, which is 23156% above median its 10-year median of 7.30 and 30028.1% above the Drug Manufacturers industry median of 5.64. Center Laboratories' overall GF Score™ is 69/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Net Margin % calculated?
Net Margin % is calculated from a company's financial statements. For Center Laboratories (ROCO:4123), the current Net Margin % is 1,697.72% as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Center Laboratories (ROCO:4123) Overvalued in 2026?
Based on GuruFocus' analysis, Center Laboratories stock appears to be undervalued.
The current stock price of NT$37.50 is trading 12.9% below its estimated GF Value™ of NT$43.04.
GuruFocus considers Center Laboratories to be Modestly Undervalued.
Key valuation signals for ROCO:4123:
Net Margin %: 1,697.72% (23156% above median its 10-year median of 7.30)
GF Value™: NT$43.04 vs. price of NT$37.50 (12.9% below fair value)
Industry Position: 30028.1% above the Drug Manufacturers median (#3 of 960)
No single metric tells the full story. See the ROCO:4123 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Center Laboratories Inc is engaged in the manufacture and sale of various Western pharmaceuticals, including Western medicine manufacturing, wholesale, and retail. The Company operates through the following segments: Pharmaceutical Division, Biotechnology Venture Capital, and Glac Segment. The Pharmaceutical Division, which generates the majority of revenue, manufactures and sells various Western pharmaceuticals. The Biotechnology Venture Capital segment invests in domestic and foreign biotechnology undertakings, while the Glac Segment manufactures and sells probiotic products. The Company operates in Taiwan, Mainland China, and other regions, with Taiwan generating the majority of revenue.
69GF Score
Get the complete analysis for ROCO:4123
Net Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ROCO:4123 has been successfully added to your 
